Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
PaperCitations, authors & open-access status
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 687 citations, 2017 year and bronze oa status.
687
Citations
2017
Year
bronze
OA Status